Literature DB >> 21498666

Cutting edge: PHLPP regulates the development, function, and molecular signaling pathways of regulatory T cells.

Scott J Patterson1, Jonathan M Han, Rosa Garcia, Kiran Assi, Tianyan Gao, Audrey O'Neill, Alexandra C Newton, Megan K Levings.   

Abstract

Regulatory T cells (Tregs) have a reduced capacity to activate the PI3K/Akt pathway downstream of the TCR, and the resulting low activity of Akt is necessary for their development and function. The molecular basis for the failure of Tregs to activate Akt efficiently, however, remains unknown. We show that PH-domain leucine-rich-repeat protein phosphatase (PHLPP), which dephosphorylates Akt, is upregulated in Tregs, thus suppressing Akt activation. Tregs expressed higher levels of PHLPP than those of conventional T cells, and knockdown of PHLPP1 restored TCR-mediated activation of Akt in Tregs. Consistent with their high Akt activity, the suppressive capacity of Tregs from PHLPP1(-/-) mice was significantly reduced. Moreover, the development of induced Tregs was impaired in PHLPP1(-/-) mice. The increased level of Akt's negative regulator, PHLPP, provides a novel mechanism used by T cells to control the Akt pathway and the first evidence, to our knowledge, for a molecular mechanism underlying the functionally essential reduction of Akt activity in Tregs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21498666      PMCID: PMC4015973          DOI: 10.4049/jimmunol.1002126

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells.

Authors:  Steven J Bensinger; Patrick T Walsh; Jidong Zhang; Martin Carroll; Ramon Parsons; Jeffrey C Rathmell; Craig B Thompson; Matthew A Burchill; Michael A Farrar; Laurence A Turka
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

2.  Defective activation of protein kinase C and Ras-ERK pathways limits IL-2 production and proliferation by CD4+CD25+ regulatory T cells.

Authors:  Somia P Hickman; Jaeseok Yang; Rajan M Thomas; Andrew D Wells; Laurence A Turka
Journal:  J Immunol       Date:  2006-08-15       Impact factor: 5.422

3.  Altered activation of AKT is required for the suppressive function of human CD4+CD25+ T regulatory cells.

Authors:  Natasha K Crellin; Rosa V Garcia; Megan K Levings
Journal:  Blood       Date:  2006-10-24       Impact factor: 22.113

4.  PTEN inhibits IL-2 receptor-mediated expansion of CD4+ CD25+ Tregs.

Authors:  Patrick T Walsh; Jodi L Buckler; Jidong Zhang; Andrew E Gelman; Nicole M Dalton; Devon K Taylor; Steven J Bensinger; Wayne W Hancock; Laurence A Turka
Journal:  J Clin Invest       Date:  2006-08-17       Impact factor: 14.808

Review 5.  The PI-3 kinase/Akt pathway and T cell activation: pleiotropic pathways downstream of PIP3.

Authors:  Lawrence P Kane; Arthur Weiss
Journal:  Immunol Rev       Date:  2003-04       Impact factor: 12.988

6.  PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth.

Authors:  Tianyan Gao; Frank Furnari; Alexandra C Newton
Journal:  Mol Cell       Date:  2005-04-01       Impact factor: 17.970

7.  PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms.

Authors:  John Brognard; Emma Sierecki; Tianyan Gao; Alexandra C Newton
Journal:  Mol Cell       Date:  2007-03-23       Impact factor: 17.970

8.  Transcription factors Foxo3a and Foxo1 couple the E3 ligase Cbl-b to the induction of Foxp3 expression in induced regulatory T cells.

Authors:  Yohsuke Harada; Yasuyo Harada; Chris Elly; Ge Ying; Ji-Hye Paik; Ronald A DePinho; Yun-Cai Liu
Journal:  J Exp Med       Date:  2010-05-03       Impact factor: 14.307

9.  Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells.

Authors:  Manuela Battaglia; Angela Stabilini; Maria-Grazia Roncarolo
Journal:  Blood       Date:  2005-03-03       Impact factor: 22.113

10.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

View more
  36 in total

1.  Pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP): a new player in cell signaling.

Authors:  Noel A Warfel; Alexandra C Newton
Journal:  J Biol Chem       Date:  2011-12-05       Impact factor: 5.157

2.  Suppression of survival signalling pathways by the phosphatase PHLPP.

Authors:  Audrey K O'Neill; Matthew J Niederst; Alexandra C Newton
Journal:  FEBS J       Date:  2012-03-16       Impact factor: 5.542

Review 3.  Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease.

Authors:  Michel DuPage; Jeffrey A Bluestone
Journal:  Nat Rev Immunol       Date:  2016-02-15       Impact factor: 53.106

Review 4.  Turning off AKT: PHLPP as a drug target.

Authors:  Alexandra C Newton; Lloyd C Trotman
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

5.  Immunosuppressive effects of the traditional Chinese herb Qu Mai on human alloreactive T cells.

Authors:  J Reid-Adam; N Yang; Y Song; P Cravedi; X-M Li; P Heeger
Journal:  Am J Transplant       Date:  2013-02-22       Impact factor: 8.086

Review 6.  Metabolic control of the Treg/Th17 axis.

Authors:  Joseph Barbi; Drew Pardoll; Fan Pan
Journal:  Immunol Rev       Date:  2013-03       Impact factor: 12.988

Review 7.  New roles for cyclin-dependent kinases in T cell biology: linking cell division and differentiation.

Authors:  Andrew D Wells; Peter A Morawski
Journal:  Nat Rev Immunol       Date:  2014-03-07       Impact factor: 53.106

Review 8.  Modulation of regulatory T cell function and stability by co-inhibitory receptors.

Authors:  Liliana E Lucca; Margarita Dominguez-Villar
Journal:  Nat Rev Immunol       Date:  2020-04-08       Impact factor: 53.106

9.  Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy.

Authors:  Muhan Chen; Dawid G Nowak; Lloyd C Trotman
Journal:  Clin Cancer Res       Date:  2014-06-15       Impact factor: 12.531

10.  Foxp3-mediated inhibition of Akt inhibits Glut1 (glucose transporter 1) expression in human T regulatory cells.

Authors:  Samik Basu; Britany Hubbard; Ethan M Shevach
Journal:  J Leukoc Biol       Date:  2014-12-09       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.